https://sinodrugwatch.ghost.io/hengrui-out-licenses-hrs-1893-structure-patent-global-race-with-aficamten-and-mavacamten/2025-11-05T18:41:57.000Zhttps://sinodrugwatch.ghost.io/libtayo-cemiplimab-receives-fda-approval-for-adjuvant-cscc-cn/2025-10-08T23:02:14.000Zhttps://sinodrugwatch.ghost.io/libtayo-cemiplimab-receives-fda-approval-for-adjuvant-cscc/2025-10-08T23:00:14.000Zhttps://sinodrugwatch.ghost.io/zenas-innocare-orelabrutinib-deal-cn/2025-10-08T18:19:30.000Zhttps://sinodrugwatch.ghost.io/zenas-innocare-orelabrutinib-deal/2025-10-08T16:01:12.000Zhttps://sinodrugwatch.ghost.io/fda-approves-jascayd-r-nerandomilast-for-idiopathic-pulmonary-fibrosis-cn/2025-10-08T05:33:51.000Zhttps://sinodrugwatch.ghost.io/fda-approves-jascayd-r-nerandomilast-for-idiopathic-pulmonary-fibrosis/2025-10-08T05:11:59.000Zhttps://sinodrugwatch.ghost.io/fda-approves-lurbinectedin-atezolizumab-es-sclc/2025-10-04T01:58:06.000Zhttps://sinodrugwatch.ghost.io/fda-approves-lurbinectedin-atezolizumab-es-sclc-cn/2025-10-04T01:49:12.000Zhttps://sinodrugwatch.ghost.io/fda-novel-drug-approvals-for-2025-precision-therapies-rare-diseases-and-chinas-growing-footprint/2025-10-03T17:42:07.000Zhttps://sinodrugwatch.ghost.io/pan-dian-2025-nian-fda-huo-pi-xin-yao-zhong-guo-chuang-xin-yao-qi-di-zao-duo-xiang-li-shi-tu-po/2025-10-03T17:41:06.000Zhttps://sinodrugwatch.ghost.io/fdapi-zhun-li-lai-imlunestrantyong-yu-esr1tu-bian-de-er-her2-wan-qi-ru-xian-yan-zhong-guo-yi-yi-shen-bao-shang-shi/2025-10-03T17:38:59.000Zhttps://sinodrugwatch.ghost.io/fda-approves-imlunestrant-for-esr1-mutated-er-her2-breast-cancer-2/2025-10-03T17:38:29.000Zhttps://sinodrugwatch.ghost.io/yan-fa-guan-xian-quan-lai-zi-zhong-guo-chuang-xin-yao-qi-tui-dong-mei-ying-sheng-wu-ji-zhu-chu-chuang-gong-si-kai-pi-xin-lu-jing/2025-10-03T17:36:57.000Zhttps://sinodrugwatch.ghost.io/china-origin-assets-exclusively-fuel-new-us-and-uk-biotech-startups-2023-2025/2025-10-03T17:36:26.000Zhttps://sinodrugwatch.ghost.io/2025nian-fdaxin-yao-wan-zheng-hui-fu-xin-crl-jie-xi-ju-pi-yuan-yin-yu-hou-xu-zou-xiang/2025-10-03T17:34:22.000Zhttps://sinodrugwatch.ghost.io/comprehensive-analysis-of-fda-crls-in-2025-patterns-sponsor-responses-and-outcomes/2025-10-03T17:33:51.000Zhttps://sinodrugwatch.ghost.io/quan-qiu-shou-ge-zhi-liao-xun-ma-zhen-nuo-hua-btkyi-zhi-ji-rui-mi-bu-ti-ni-huo-pi-zai-mei-shang-shi/2025-10-03T17:32:01.000Zhttps://sinodrugwatch.ghost.io/novartis-rhapsido-r-remibrutinib-fda-approved-as-first-oral-btk-inhibitor-for-chronic-spontaneous-urticaria/2025-10-03T17:31:24.000Zhttps://sinodrugwatch.ghost.io/triastek-files-chinas-first-3d-printed-drug-nda-t20j-apixaban/2025-10-03T17:30:07.000Zhttps://sinodrugwatch.ghost.io/san-die-ji-ti-jiao-zhong-guo-shou-kuan-3dda-yin-yao-wu-t20j-a-pai-sha-ban-pian-shang-shi-shen-qing/2025-10-03T17:28:55.000Zhttps://sinodrugwatch.ghost.io/nuo-he-nuo-de-liang-kuan-xin-yao-zai-mei-di-jiao-shang-shi-shen-qing-yi-ke-yi-dao-su-yu-mim8/2025-10-03T17:27:05.000Zhttps://sinodrugwatch.ghost.io/novo-nordisk-resubmits-awiqli-r-and-submits-mim8-bla-to-fda-for-diabetes-and-hemophilia-a/2025-10-03T17:26:42.000Zhttps://sinodrugwatch.ghost.io/bai-ji-shen-zhou-zhuan-li-jiu-fen-luo-mu-shou-du-ying-li-qian-zhi-rui-shi-mai-xiang-quan-qiu-zhong-liu-ju-tou-zhi-lu/2025-10-03T17:23:45.000Zhttps://sinodrugwatch.ghost.io/beone-resolves-abbvie-patent-dispute-as-brukinsa-powers-first-profit-and-swiss-rebrand/2025-10-03T17:23:18.000Zhttps://sinodrugwatch.ghost.io/nuo-he-nuo-de-ling-tou-crystalys-2-05-yi-mei-yuan-rong-zi-zhu-tui-wei-cai-tong-feng-yao-duo-ti-nuo-lei-ou-mei-lin-chuang/2025-09-30T23:13:51.000Zhttps://sinodrugwatch.ghost.io/crystalys-launches-with-205m-to-advance-dotinurad-globally-already-approved-in-china-by-eisai/2025-09-30T22:40:51.000Zhttps://sinodrugwatch.ghost.io/metseragong-bu-met-097i-iibqi-ding-xian-shu-ju-hui-rui-73yi-mei-yuan-shou-gou-jia-su-quan-qiu-iiiqi-lin-chuang-qi-dong/2025-09-30T00:03:49.000Zhttps://sinodrugwatch.ghost.io/pfizers-7-3b-obesity-gamble-pays-early-with-met-097i-phase-2b-success/2025-09-29T23:55:08.000Zhttps://sinodrugwatch.ghost.io/shou-ge-guo-chan-hpv-si-jie-yi-miao-ai-wei-jia-huo-pi-wan-cheng-quan-xi-lie-guo-chan-hua/2025-09-29T16:09:00.000Zhttps://sinodrugwatch.ghost.io/china-approves-first-domestic-quadrivalent-hpv-vaccine/2025-09-29T16:01:07.000Zhttps://sinodrugwatch.ghost.io/gan-li-yao-ye-xi-shou-ba-xi-fiocruzyu-biommqian-shu-10nian-yi-dao-su-ben-tu-hua-xie-yi/2025-09-29T04:06:40.000Zhttps://sinodrugwatch.ghost.io/chinas-gan-lee-to-localize-insulin-production-in-brazil-via-10-year-partnership/2025-09-29T03:43:29.000Zhttps://sinodrugwatch.ghost.io/chinas-oral-glp-1-surge-rising-amid-global-setbacks-and-intensifying-competition/2025-09-26T04:12:37.000Zhttps://sinodrugwatch.ghost.io/luo-shi-pharma-day-2025yao-dian-yan-fa-ju-jiao-dai-xie-guan-xian-kuo-zhan-ji-35yi-bing-gou-89bio/2025-09-26T03:59:33.000Zhttps://sinodrugwatch.ghost.io/li-lai-yin-zhan-lue-yuan-yin-zhong-zhi-bimagrumabfei-pang-zheng-2bqi-lin-chuang-shi-yan/2025-09-25T15:13:35.000Zhttps://sinodrugwatch.ghost.io/eli-lilly-halts-phase-2b-obesity-trial-for-bimagrumab-citing-strategic-reasons/2025-09-25T15:12:06.000Zhttps://sinodrugwatch.ghost.io/roche-pharma-day-2025-chf24bn-pharma-obesity-push-and-r-d-acceleration/2025-09-24T16:01:15.000Zhttps://sinodrugwatch.ghost.io/uniqure-amt-130-ji-yin-liao-fa-zai-heng-ting-dun-bing-shi-yan-zhong-qu-de-tu-po-xing-jin-zhan-gu-jie-biao-sheng-194/2025-09-24T15:21:05.000Zhttps://sinodrugwatch.ghost.io/uniqures-amt-130-achieves-landmark-success-in-huntingtons-disease-trial/2025-09-24T15:19:19.000Zhttps://sinodrugwatch.ghost.io/heng-rui-yu-glenmark-qian-shu-chao-11-yi-mei-yuan-rui-kang-qu-tuo-zhu-dan-kang-hai-wai-shou-quan-xu-ke/2025-09-24T15:03:43.000Zhttps://sinodrugwatch.ghost.io/hengrui-and-glenmark-strike-1-1b-adc-deal-for-trastuzumab-rezetecan-shr-a1811/2025-09-24T14:50:52.000Zhttps://sinodrugwatch.ghost.io/you-yu-biao-zhun-liao-fa-luo-shi-kou-fu-ru-xian-yan-xin-yao-giredestransan-qi-cheng-gong/2025-09-23T18:59:07.000Zhttps://sinodrugwatch.ghost.io/roche-reports-positive-phase-iii-for-giredestrant-combo-after-cdk4-6-progression/2025-09-23T16:01:48.000Zhttps://sinodrugwatch.ghost.io/ge-li-asc47lian-he-si-mei-ge-lu-tai-jian-zhong-ti-sheng-56-2-xian-zhu-gai-shan-wei-chang-nai-shou-xing/2025-09-23T04:04:36.000Zhttps://sinodrugwatch.ghost.io/ascletis-asc47-combo-with-semaglutide-shows-56-greater-weight-loss-better-gi-safety/2025-09-23T03:59:50.000Zhttps://sinodrugwatch.ghost.io/hui-rui-ni-yi-73yi-mei-yuan-shou-gou-metsera-bu-ju-qian-zai-yue-du-gei-yao-de-xin-yi-dai-jian-fei-liao-fa/2025-09-23T03:49:28.000Zhttps://sinodrugwatch.ghost.io/pfizer-finalizes-7-3b-metsera-buy-for-next-gen-obesity-therapy-with-monthly-dosing/2025-09-23T03:43:35.000Zhttps://sinodrugwatch.ghost.io/from-discovery-to-fda-approval-forzinity-becomes-first-therapy-for-barth-syndrome/2025-09-21T22:05:41.000Zhttps://sinodrugwatch.ghost.io/quan-qiu-shou-kuan-han-jian-bing-ba-si-zong-he-zheng-liao-fa-elamipretidehuo-fdajia-su-pi-zhun/2025-09-21T22:03:49.000Zhttps://sinodrugwatch.ghost.io/jing-fang-yi-yao-cheng-gong-shang-shi-gang-jiao-suo-krasba-xiang-chuang-xin-yin-ling-zhong-guo-yao-qi/2025-09-20T17:01:56.000Zhttps://sinodrugwatch.ghost.io/genfleet-therapeutics-blockbuster-ipo-highlights-chinas-kras-innovation-and-g12d-ambitions/2025-09-20T16:01:42.000Zhttps://sinodrugwatch.ghost.io/1-2fen-zhong-wan-cheng-gei-yao-mo-sha-dong-kyao-pi-xia-zhu-she-ji-huo-fdapi-zhun/2025-09-20T05:11:27.000Zhttps://sinodrugwatch.ghost.io/keytruda-subcutaneous-injection-receives-fda-approval-1-2-minute-dosing-for-most-solid-tumors/2025-09-20T05:00:03.000Zhttps://sinodrugwatch.ghost.io/zhong-guo-chuang-xin-yao-qi-chu-hai-xin-qu-shi-newcomo-shi-jia-su-quan-qiu-shi-chang-jing-zheng-li-2024-2025/2025-09-20T04:19:15.000Zhttps://sinodrugwatch.ghost.io/the-rise-of-the-newco-model-in-chinese-biotech-global-expansion-via-spinouts-2024-2025/2025-09-19T16:05:55.000Zhttps://sinodrugwatch.ghost.io/quan-qiu-shou-ge-shen-bao-shang-shi-de-protacyao-wu-vepdegestrant-ji-yu-bei-hou-de-lin-chuang-yu-shang-ye-tiao-zhan/2025-09-19T04:47:37.000Zhttps://sinodrugwatch.ghost.io/vepdegestrant-first-protac-at-the-fda-gate-promise-meets-clinical-and-commercial-hurdles/2025-09-18T16:02:08.000Zhttps://sinodrugwatch.ghost.io/mo-sha-dong-di-yi-san-gong-cdh6ba-xiang-adc-raludotatug-deruxtecanhuo-fdatu-po-xing-liao-fa-ren-ding/2025-09-17T16:51:11.000Zhttps://sinodrugwatch.ghost.io/raludotatug-deruxtecan-first-in-class-cdh6-adc-earns-fda-breakthrough-status/2025-09-17T16:02:42.000Zhttps://sinodrugwatch.ghost.io/mabwell-and-aditum-launch-kalexo-bio-to-advance-dual-target-sirna-therapy-in-newco-spinout/2025-09-17T15:26:03.000Zhttps://sinodrugwatch.ghost.io/mai-wei-sheng-wu-xi-shou-aditum-cheng-li-kalexo-bio-tui-jin-shuang-ba-dian-sirna-yao-wu-newco-chu-hai/2025-09-17T15:24:29.000Zhttps://sinodrugwatch.ghost.io/genmab-halts-pro1107-and-the-evolving-ptk7-adc-landscape/2025-09-17T04:28:14.000Zhttps://sinodrugwatch.ghost.io/ptk7ba-xiang-adczui-xin-jin-zhan-genmabzhong-zhi-pro1107-ke-lun-bo-tai-skb518ling-pao-lin-chuang/2025-09-17T04:08:27.000Zhttps://sinodrugwatch.ghost.io/triple-drug-therapy-for-cystic-fibrosis-wins-2025-lasker-award/2025-09-15T16:01:58.000Zhttps://sinodrugwatch.ghost.io/novo-nordisk-secures-first-oral-glp-1-cardiovascular-approval-in-eu/2025-09-15T15:20:17.000Zhttps://sinodrugwatch.ghost.io/ai-meets-experimental-science-llms-accelerate-discovery-in-molecular-microbiology/2025-09-15T00:27:31.000Zhttps://sinodrugwatch.ghost.io/cong-shi-yan-dao-jia-she-ai-co-scientist-ru-he-zhong-xian-fen-zi-wei-sheng-wu-xue-ji-zhi/2025-09-15T00:17:10.000Zhttps://sinodrugwatch.ghost.io/pharma-at-a-turning-point-2025-global-recalibration-strategic-pullbacks-and-chinas-out-licensing-surge/2025-09-14T18:26:55.000Zhttps://sinodrugwatch.ghost.io/bms-may-exit-shanghai-squibb-jv-closing-chapter-for-the-first-sino-u-s-pharma-partnership/2025-09-14T18:13:29.000Zhttps://sinodrugwatch.ghost.io/bai-shi-mei-shi-gui-bao-huo-jiang-chu-shou-zhong-mei-shang-hai-shi-gui-bao-shou-jia-zhong-mei-he-zi-yao-qi-zou-xiang-xie-mu/2025-09-14T18:11:17.000Zhttps://sinodrugwatch.ghost.io/analysis-chinas-hpv-vaccine-market-in-2025-nip-inclusion-price-wars-and-market-dynamics/2025-09-13T17:01:17.000Zhttps://sinodrugwatch.ghost.io/pharma-reshaping-2025-cost-rationalization-strategic-partnerships-and-chinas-innovation-drive/2025-09-13T01:30:16.000Zhttps://sinodrugwatch.ghost.io/baili-pharmas-bl-m07d1-enters-phase-iii-in-her2-mutant-nsclc-challenging-keytruda-head-on/2025-09-12T15:24:46.000Zhttps://sinodrugwatch.ghost.io/maze-therapeutics-mze782-shows-strong-phase-1-data-targets-pku-and-ckd/2025-09-12T00:30:29.000Zhttps://sinodrugwatch.ghost.io/kn026-anbenitamab-nda-accepted-by-nmpa-first-domestic-her2-bispecific-in-gastric-cancer/2025-09-11T16:03:40.000Zhttps://sinodrugwatch.ghost.io/daraxonrasib-emerges-as-a-promising-contender-in-metastatic-pancreatic-cancer/2025-09-11T04:40:19.000Zhttps://sinodrugwatch.ghost.io/1-4-billion-deal-novartis-buys-tourmaline-bio-and-its-phase-3-ready-il-6-antibody-pacibekitug/2025-09-10T17:33:42.000Zhttps://sinodrugwatch.ghost.io/yoltech-therapeutics-raises-45m-in-series-b-to-advance-in-vivo-gene-editing-pipeline-toward-phase-3/2025-09-10T16:02:28.000Zhttps://sinodrugwatch.ghost.io/dual-pd-l1-x-vegf-a-antibody-pumitamig-delivers-strong-phase-2-results-in-es-sclc/2025-09-09T16:01:30.000Zhttps://sinodrugwatch.ghost.io/hengruis-180m-ctla-4-antibody-shr-8068-enters-late-stage-lung-cancer-trial/2025-09-09T05:17:59.000Zhttps://sinodrugwatch.ghost.io/fosun-pharma-advances-hlx17-and-saf-189-strengthening-global-and-domestic-oncology-footprints/2025-09-09T04:54:10.000Zhttps://sinodrugwatch.ghost.io/ideaya-and-hengruis-dll3-adc-ide849-shows-promising-phase-1-results-at-wclc-2025/2025-09-08T16:01:11.000Zhttps://sinodrugwatch.ghost.io/cn/2025-wclcgun-mcla-129zhi-liao-wan-qi-nsclcde-1qi-yan-jiu-geng-xin-jie-guo-gong-bu/2025-09-08T14:05:32.000Zhttps://sinodrugwatch.ghost.io/iza-bren-bl-b01d1-bispecific-egfr-her3-adc-shows-promise-in-egfr-mutated-nsclc/2025-09-08T06:38:56.000Zhttps://sinodrugwatch.ghost.io/harmoni-phase-3-ivonescimab-confirms-pfs-benefit-os-primary-endpoint-not-met-nominal-in-follow-up-analysis/2025-09-08T00:41:21.000Zhttps://sinodrugwatch.ghost.io/naperiglipron-trial-terminations-highlight-shifts-in-oral-glp-1-market/2025-09-06T22:36:42.000Zhttps://sinodrugwatch.ghost.io/breakthroughs-from-acs-fall-2025-13-first-time-drug-structure-disclosures-across-6-major-disease-areas/2025-09-06T22:35:54.000Zhttps://sinodrugwatch.ghost.io/aficamten-discovery-and-phase-3-insights-vs-mavacamten-in-hypertrophic-cardiomyopathy/2025-09-06T18:07:19.000Zhttps://sinodrugwatch.ghost.io/db-1303-bnt323-phase-iii-success-in-her2-positive-breast-cancer-strengthens-duality-biontech-alliance/2025-09-05T16:03:15.000Zhttps://sinodrugwatch.ghost.io/semaglutide-mania-in-china-inside-the-biosimilar-gold-rush/2025-09-03T21:51:06.000Zhttps://sinodrugwatch.ghost.io/lilly-advances-muvalaplin-into-phase-iii-in-china-first-oral-lp-a-lowering-therapy-targeting-mace-risk/2025-09-03T17:01:18.000Zhttps://sinodrugwatch.ghost.io/novartis-deepens-rnai-partnership-with-argo-biopharma-in-5-36b-cardiovascular-deal/2025-09-03T16:02:56.000Zhttps://sinodrugwatch.ghost.io/enlicitides-phase-3-triumphs-herald-new-era-for-pcsk9-inhibitors-and-cholesterol-management/2025-09-03T06:15:35.000Zhttps://sinodrugwatch.ghost.io/hengruis-hrs9531-nda-accepted-in-china-first-homegrown-glp-1-gip-dual-agonist-to-challenge-tirzepatide/2025-09-01T20:04:13.000Zhttps://sinodrugwatch.ghost.io/chinas-60b-out-licensing-boom-in-2025-positions-biotech-as-global-powerhouse-in-oncology-obesity/2025-09-01T19:55:50.000Zhttps://sinodrugwatch.ghost.io/wclc-2025-china-origin-bnt327-pd-l1-vegf-a-delivers-breakthrough-es-sclc-results/2025-09-01T17:45:46.000Zhttps://sinodrugwatch.ghost.io/ryzneuta-r-highlights-the-14x-china-u-s-drug-pricing-gap/2025-09-01T17:41:29.000Zhttps://sinodrugwatch.ghost.io/dpp1-inhibitors-first-fda-approval-chinas-fast-follow-pipeline/2025-09-01T17:40:21.000Zhttps://sinodrugwatch.ghost.io/fda-approval-of-brensocatib-signals-new-era-for-ncfb-treatment-strategic-implications-for-chinas-respiratory-pipeline/2025-09-01T17:39:35.000Zhttps://sinodrugwatch.ghost.io/biotech-ipos-surge-through-august-2025-hengrui-leads-asia-u-s-market-selective/2025-09-01T01:38:02.000Zhttps://sinodrugwatch.ghost.io/from-first-in-class-to-finest-how-best-in-class-drugs-reshape-pharmaceutical-leadership/2025-09-01T00:46:48.000Zhttps://sinodrugwatch.ghost.io/ivonescimab-secures-pivotal-os-win-in-nsclc-redefining-the-pd-1-vegf-bispecific-landscape/2025-08-31T19:55:32.000Zhttps://sinodrugwatch.ghost.io/zanubrutinib-surpasses-ibrutinib-a-case-study-in-best-in-class-innovation/2025-08-31T19:43:44.000Zhttps://sinodrugwatch.ghost.io/china-biotech-phase-iii-pipeline-august-2025-10-newly-disclosed-trials/2025-08-28T16:02:23.000Zhttps://sinodrugwatch.ghost.io/global-pd-l1-adc-race-heats-up-as-pfizers-pf-08046054-becomes-first-in-phase-iii/2025-08-28T15:19:12.000Zhttps://sinodrugwatch.ghost.io/beyond-ivonescimab-chinas-next-billion-pd-1-vegf-bispecific-licensing-opportunities/2025-08-27T18:04:58.000Zhttps://sinodrugwatch.ghost.io/china-pharma-pulse-innovation-reform-global-dealmaking-surge/2025-08-27T04:02:54.000Zhttps://sinodrugwatch.ghost.io/from-fast-follower-to-first-in-class-innovator-chinas-2015-2025-drug-revolution/2025-08-27T04:01:06.000Zhttps://sinodrugwatch.ghost.io/chinas-biotech-boom-top-outbound-deals-signal-global-innovation-leadership/2025-08-26T05:54:14.000Zhttps://sinodrugwatch.ghost.io/bispecific-antibodies-in-oncology-and-beyond-clinical-advances-market-growth-and-chinas-emergence/2025-08-25T17:00:01.000Zhttps://sinodrugwatch.ghost.io/beone-medicines-sells-imdelltra-r-ex-china-royalties-to-royalty-pharma-for-885m-upfront/2025-08-25T14:08:44.000Zhttps://sinodrugwatch.ghost.io/from-9-approvals-to-price-wars-the-changing-cdk4-6-landscape-in-china-and-its-u-s-contrast/2025-08-25T01:15:57.000Zhttps://sinodrugwatch.ghost.io/ai-meets-longevity-openai-and-retro-biosciences-design-next-gen-proteins/2025-08-23T06:28:29.000Zhttps://sinodrugwatch.ghost.io/h1-2025-pharma-earnings-key-takeaways-from-chinese-and-global-players/2025-08-22T13:58:35.000Zhttps://sinodrugwatch.ghost.io/bio-thera-expands-tocilizumab-biosimilar-reach-through-stada-partnership/2025-08-21T16:02:54.000Zhttps://sinodrugwatch.ghost.io/akeso-advances-non-oncology-portfolio-with-ankylosing-spondylitis-phase-iii-win/2025-08-21T14:09:43.000Zhttps://sinodrugwatch.ghost.io/dual-target-anti-vegf-race-heats-up-with-remegen-santen-180m-deal/2025-08-20T16:03:11.000Zhttps://sinodrugwatch.ghost.io/uneven-gains-mounting-risks-pharma-giants-navigate-chinas-evolving-market-landscape/2025-08-17T18:24:49.000Zhttps://sinodrugwatch.ghost.io/china-online-pharmacy-sales-break-700b-yuan-semaglutide-surges-142-to-top/2025-08-16T15:41:41.000Zhttps://sinodrugwatch.ghost.io/chinas-biotech-ipo-comeback-sparked-by-innogens-285-debut/2025-08-15T05:35:52.000Zhttps://sinodrugwatch.ghost.io/qlc5508-adc-phase-1-results-positive-in-es-sclc-qilu-to-commercialize-in-china/2025-08-14T16:02:41.000Zhttps://sinodrugwatch.ghost.io/breaking-nhsa-releases-preliminary-review-results-for-2025-national-reimbursement-drug-list-and-commercial-innovative-drug-catalog/2025-08-12T05:33:27.000Zhttps://sinodrugwatch.ghost.io/chinas-pharmaceutical-renaissance-bispecific-antibodies-innovation-and-global-impact-2015-2024/2025-08-11T16:29:23.000Zhttps://sinodrugwatch.ghost.io/fosun-pharma-bets-on-dpp-1-inhibition-for-global-respiratory-market-with-645m-out-licensing-deal/2025-08-11T15:18:38.000Zhttps://sinodrugwatch.ghost.io/china-approves-boyouping-r-ba5101-the-worlds-first-dulaglutide-biosimilar-and-first-domestic-product/2025-08-10T18:20:22.000Zhttps://sinodrugwatch.ghost.io/new-frontier-of-bispecific-antibody-bd-in-china-after-pd-l-1-vegf/2025-08-08T21:01:28.000Zhttps://sinodrugwatch.ghost.io/chinas-cgt-surge-unpacking-a-nature-review-on-regulatory-reform-pipeline-trends-global-implications/2025-08-08T14:59:45.000Zhttps://sinodrugwatch.ghost.io/chinas-nuclear-medicine-networks-leaders-challenges-and-growth-potential/2025-08-07T21:51:58.000Zhttps://sinodrugwatch.ghost.io/madrigal-secures-2b-deal-for-cspcs-preclinical-glp-1-2/2025-08-06T00:52:51.000Zhttps://sinodrugwatch.ghost.io/xtalpi-and-dovetree-ink-6-billion-ai-powered-drug-discovery-deal/2025-08-06T00:47:38.000Z